Jornal Médico – Treating HF with reduced ejection fraction early and with the four pillars of treatment at target doses… now!
Treating HF with reduced ejection fraction early and with the four pillars of treatment at target doses… now! As part of ESC 2023, Novartis organized a symposium on the theme “Treating patients living with heart failure: Are we really doing enough?”. In this session moderated by Carolyn Lam, a specialist from the National Heart Center […]
Jornal Médico – ATTR-CM: essential to identify the signs of disease, treat early and follow the patient individually
ATTR-CM: essential to identify the signs of disease, treat early and follow the patient individually On the second day of ESC 2023, a symposium promoted by Pfizer took place on the theme “The journey to improved outcomes in transthyretin amyloid cardiomyopathy (ATTR-CM)”. Attending the session was Francisco Sampaio and, therefore, Jornal Médico spoke with the […]
Jornal Médico – Joana Ferreira: the influence of the course of the disease on the prognosis of patients with slightly depressed ejection fraction
Joana Ferreira: the influence of disease trajectory on the prognosis of patients with slightly depressed ejection fraction The moderated session “Heart failure outcomes: effects of phenotypes and comorbidities”, within the scope of ESC 2023, was attended by Joana Ferreira, who presented the ePoster “Heart failure with mildly reduced ejection fraction is not all alike: the […]